Business
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quar
About this update from Crinetics Pharmaceuticals, Inc.
[{"type":"image","alt":"Crinetics Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Crinetics Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/524edf87ef8b0571a758e030125d56ba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/im.J1fsS6fGk_Ux606V2mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Mw--/https://media.zenfs.com/en/globenewswire.com/524edf87ef8b0571a758e030125d56ba","width":300,"height":102},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/im.J1fsS6fGk_Ux606V2mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Mw--/https://media.zenfs.com/en/globenewswire.com/524edf87ef8b0571a758e030125d56ba","width":300,"height":102}},"lazy":false},{"type":"text","content":" PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter ","length":133,"tagName":"p"},{"type":"text","content":"Management Hosting Conference Call at 4:30 p.m. ET Today","length":56,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2026.","length":335,"tagName":"p"},{"type":"text","content":"“We are extremely pleased with the significant impact that Palsonify is making across the community. This is illustrated by the strong adoption of Palsonify by healthcare providers and the positive patient response to treatment,” said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. “The significant growth in our unique prescriber base reflects a growing confidence among endocrinologists in the compelling clinical data and proven efficacy of Palsonify. Expanding clinical adoption is fueling sustained demand, evidenced by the steady growth trend in new patient start forms. We are seeing an increasingly efficient path to treatment for patients as the reimbursement environment matures. These results reinforce our confidence in the long-term commercial trajectory of Palsonify and our ability to deliver transformative therapies at scale.”","length":870,"tagName":"p"},{"type"...